| Literature DB >> 29713565 |
Leticia Dias Lima Jedlicka1,2, Sheila Barreto Guterres1,3, Aleksandro Martins Balbino1, Giuseppe Bruno Neto1, Richardt Gama Landgraf1, Liliam Fernandes1, Emanuel Carrilho4, Etelvino José Henriques Bechara1,5, Nilson A Assuncao1.
Abstract
BACKGROUND: Acetylation alters several protein properties including molecular weight, stability, enzymatic activity, protein-protein interactions, and other biological functions. Our previous findings demonstrating that diacetyl/peroxynitrite can acetylate L-lysine, L-histidine, and albumin in vitro led us to investigate whether diacetyl-treated rats suffer protein acetylation as well.Entities:
Keywords: Diacetyl; Food additive; Lung diseases; Proteomics.; Radical acetylation
Year: 2018 PMID: 29713565 PMCID: PMC5923218 DOI: 10.7717/peerj.4688
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Composition of the tested buffers.
| Composition | Buffer 1 | Buffer 2 | Buffer 3 |
|---|---|---|---|
| Buffering agent | Tris 25 mM | Tris 25 mM | Tris 25 mM |
| Surfactant | CHAPS 2% | CHAPS4% TRITON 1% | CHAPS 4% |
| Protease inhibitors | Aprotinine, leupeptine, pepstatine, benzamidine and PMSF | Aprotinine, leupeptine, pepstatine, benzamidine and PMSF | Aprotinine, leupeptine, pepstatine, benzamidine and PMSF |
| Chaotropes | 7 M Urea | ||
| 2 M Thiourea | |||
| Reducer | 65 mM DTT |
Notes.
Buffer 1 with power low solubility (few surfactants without chaotropes).
Buffer 2 with median solubilizing power (more surfactants).
Buffer 3 with maximum solubilization power (presence of chaotropes, surfactants and reducers).
Figure 1Comparison of the amount of total protein present in the lysate and the resolubilizated proteins (precipitate proteins resuspended) using lung tissue.
Target proteins, acetylated proteins in group treated with diacetyl but non-acetylated in control group.
| Protein I.D. | Gene I.D. | Meta score control | Meta score treated | Peptides control | Peptides treated | *SC [%] control | *SC [%] treated |
|---|---|---|---|---|---|---|---|
| AL1A1 | 269.1 | 253.5 | 11 | 9 | 37.1 | 31.7 | |
| ANXA2 | 539.6 | 284.6 | 13 | 13 | 44.5 | 43.7 | |
| ANXA5 | 411 | 265 | 10 | 10 | 37.3 | 43.6 | |
| ASS1 | 71 | 1,030.1 | 3 | 21 | 20.6 | 64.3 | |
| BHMT1 | 172.3 | 834.8 | 7 | 24 | 30 | 63.1 | |
| CARL | 277.1 | 607.2 | 8 | 13 | 31.7 | 49.5 | |
| CES1D | 598.6 | 571.1 | 15 | 16 | 38.8 | 50.8 | |
| DNAHC1 | 1,391.9 | 1,603.7 | 77 | 89 | 23.5 | 27.7 | |
| EEF2K | 354 | 304.5 | 18 | 17 | 38.5 | 34.1 | |
| HSP90B1 | 742.6 | 492.2 | 25 | 16 | 29.6 | 23.5 | |
| EPHA6 | 486.4 | 361.4 | 27 | 20 | 32.4 | 24.5 | |
| FABPL | 120.5 | 779.4 | 3 | 16 | 36.2 | 81.9 | |
| GAPDH | 486.7 | 763 | 14 | 18 | 53.8 | 62.2 | |
| MEGEA5 | 308.5 | 353.6 | 16 | 19 | 26.7 | 31.6 | |
| PARK7 | 173.3 | 187.5 | 4 | 10 | 28.6 | 51.3 | |
| PRRC2A | 776.2 | 670.4 | 43 | 36 | 25.3 | 23.6 | |
| SI1L1 | 575.9 | 672.1 | 32 | 37 | 27.9 | 30.7 | |
| STIP1 | 189.5 | 258.9 | 10 | 14 | 22.1 | 30 | |
| PARS2 | 171.2 | 183.4 | 9 | 10 | 32.6 | 46.3 | |
| TUBB4B | 801.7 | 463.1 | 20 | 15 | 52.1 | 48.8 | |
| TPP1 | 99.3 | 109.3 | 5 | 6 | 9.9 | 11.7 | |
| UBR4 | 1,600.3 | 1,813.1 | 90 | 103 | 24.2 | 30.2 | |
| UGT2B | 390.2 | 705.3 | 21 | 25 | 44.7 | 59.1 |
Peptides from acetylated proteins in group treated with diacetyl but non-acetylated in control group.
| Protein I.D. | Gene I.D. | Peptide sequence | Peptide meta score control | Peptide meta score treated | Acetylation treated group |
|---|---|---|---|---|---|
| AL1A1_RAT | ALDH1A1 | -.MSSPAQPAVPAPLANLKIQHTK.I | 15.4 | 16.1 | 7; 20; 22 |
| ANXA2_RAT | ANXA2 | K.ELPSAMKSALSGHLETVMLGLLK.T | 15 | 21.7 | 3; 23 |
| ANXA2_RAT | ANXA2 | K.ELPSAMKSALSGHLETVMLGLLK.T | 15 | 16.6 | 3; 23 |
| ANXA2_RAT | ANXA2 | K.GVDEVTIVNILTNR.S | 71.9 | 18.2 | 14 |
| ANXA2_RAT | ANXA2 | K.SALSGHLETVMLGLLK.T | 94 | 18.6 | 6 |
| ANXA5_RAT | ANXA5 | K.YMTISGFQIEETIDRETSGNLENLLLAVVK.S | 16.4 | 16.7 | 15 |
| ANXA5_RAT | ANXA5 | K.YMTISGFQIEETIDRETSGNLENLLLAVVK.S | 16.4 | 17.6 | 5; 30 |
| ASSY_RAT | ASS1 | R.GIYETPAGTILYHAHLDIEAFTMDR.E | 39.8 | 16.1 | 13; 5 |
| BHMT1_RAT | BHMT | R.IASGRPYNPSMSKPDAWGVTK.G | 16.3 | 17.5 | 5 |
| BHMT1_RAT | BHMT | R.IASGRPYNPSMSKPDAWGVTK.G | 15.4 | 15.4 | 21; 30 |
| CALR_RAT | CALR | K.HEQNIDCGGGYVK.L | 33 | 85.7 | 13 |
| CES1D_RAT | CES1D | K.GKVLGK.Y | 24.4 | 15.1 | 2 |
| CES1D_RAT | CES1D | R.SHRDAGAPTFMYEFEYRPSFVSAMRPK.T | 18.5 | 22.7 | 2; 25 |
| CES1D_RAT | CES1D | R.SHRDAGAPTFMYEFEYRPSFVSAMRPK.T | 18.5 | 15.7 | 2; 7; 25 |
| DYH1_RAT | DNAH1 | R.SSLTRLASHMAEYECFQVELSK.N | 19 | 16.7 | 5 |
| EF2K_RAT | EEF2K | R.SGDLYTQAAEAAMEAMK.G | 30.7 | 21.1 | 7 |
| ENPL_RAT | HSP90B1 | R.MMKLIINSLYK.N | 18.8 | 16.1 | 1; 3 |
| EPHA6_RAT | EPHA6 | R.EASIMGQFDHPNIIRLEGVVTK.R | 18.3 | 16.8 | 0; 5 |
| EPHA6_RAT | EPHA6 | K.SVTEFNGDTITNTMTLGDIVYK.R | 28.2 | 50.8 | 22 |
| FABPL_RAT | FABPL | K.SVTEFNGDTITNTMTLGDIVYK.R | 16 | 36.2 | 22 |
| FABPL_RAT | FABPL | K.YQVQSQENFEPFMK.A | 28.2 | 33.9 | 4 |
| G3P_RAT | GAPDH | K.RVIISAPSADAPMFVMGVNHEK.Y | 18.6 | 23.1 | 1; 20; 22 |
| G3P_RAT | GAPDH | K.RVIISAPSADAPMFVMGVNHEK.Y | 18.6 | 15.8 | 20; 22 |
| G3P_RAT | GAPDH | K.RVIISAPSADAPMFVMGVNHEK.Y | 18.6 | 15.8 | 20; 22 |
| G3P_RAT | GAPDH | K.RVIISAPSADAPMFVMGVNHEK.Y | 18.6 | 23.1 | 1; 20; 22 |
| OGA_RAT | MGEA5 | K.LDQVSQFGCRSFALLFDDIDHNMCAADK.E | 20 | 15.4 | 21; 28 |
| PARK7_RAT | PARK7 | K.GAEEMETVIPVDIMR | 28.2 | 16.1 | 5; 6 |
| PRC2A_RAT | PRRC2A | K.ALYPGALGRPPPMPPMNFDPRWMMIPPYVDPR.L | 17.9 | 30.3 | 9 |
| PRC2A_RAT | PRRC2A | K.ALYPGALGRPPPMPPMNFDPRWMMIPPYVDPR.L | 17.9 | 18.9 | 9 |
| PRC2A_RAT | PRRC2A | K.ALYPGALGRPPPMPPMNFDPRWMMIPPYVDPR.L | 17.9 | 16.6 | 21 |
| PRC2A_RAT | PRRC2A | K.ALYPGALGRPPPMPPMNFDPRWMMIPPYVDPR.L | 17.9 | 26.6 | 21; 32 |
| PRC2A_RAT | PRRC2A | K.ALYPGALGRPPPMPPMNFDPRWMMIPPYVDPR.L | 17.9 | 19.4 | 32 |
| PRC2A_RAT | PRRC2A | K.ALYPGALGRPPPMPPMNFDPRWMMIPPYVDPR.L | 17.9 | 15.1 | 9 |
| PRC2A_RAT | PRRC2A | K.AVGTPGGNSGGAGPGISTMSRGDLSQR.A | 18.4 | 22 | 21; 27 |
| PRC2A_RAT | PRRC2A | R.ERSDSGGSSSEPFER.H | 17.1 | 15.4 | 15 |
| SI1L1_RAT | SIPA1L1 | K.EKSKPYPGAELSSMGAIVWAVR.A | 15.6 | 19.4 | 2 |
| SI1L1_RAT | SIPA1L1 | K.SLPLRRPSYTLGMK.S | 19.5 | 16.8 | 5 |
| STIP1_RAT | STIP1 | R.RAMADPEVQQIMSDPAMR.L | 20.7 | 18.9 | 1; 8 |
| STIP1_RAT | STIP1 | R.RAMADPEVQQIMSDPAMR.L | 20.7 | 20.4 | 8 |
| SYPM_RAT | PARS2 | K.GIEVGHTFYLGTKYSSIFNAHFTNA HGESLLAEMGCYGLGVTR.I | 17.8 | 15 | 21; 26 |
| TBB4B_RAT | TUBB4B | R.INVYYNEATGGKYVPR.A | 21.9 | 15.4 | 6; 12 |
| TPP1_RAT | TPP1 | R.EREPELAQLLVDQIYENAMIAAGLVDDPR.A | 15.2 | 19.3 | 29 |
| TPP1_RAT | TPP1 | R.INTLQAIWMMDPK.D | 15.9 | 15.1 | 3 |
| UBR4_RAT | UBR4 | K.ALGTLGMTTNEKGQVVTK.T | 15.7 | 21.7 | 2 |
| UBR4_RAT | UBR4 | K.EKAAPPPPPPPPPLESSPR.V | 18.3 | 18.1 | 2; 9 |
| UBR4_RAT | UBR4 | K.EKEGESSGSQEDQLCTALVNQLNR.F | 17.1 | 16.7 | 2; 24 |
| UBR4_RAT | UBR4 | K.FLSRPALPFILRLLR.G | 15.1 | 30 | 5; 12 |
| UBR4_RAT | UBR4 | R.DNPEATQQMNDLIIGKVSTALK.G | 28.8 | 17.2 | 6; 22 |
| UBR4_RAT | UBR4 | R.DNPEATQQMNDLIIGKVSTALK.G | 17.3 | 21 | 22 |
| UBR4_RAT | UBR4 | R.MAGVMAQCGGLQCMLNRLAGVK.D | 19.3 | 23.9 | 7 |
| UBR4_RAT | UBR4 | R.TGSTSSKEEDYESDAATIVQK.C | 19.4 | 17.3 | 7; 21 |
| UD2B2_RAT | UGT2B | K.EWDTFYSEILGRPTTVDETMSKVEIWLIR.S | 15.2 | 16.8 | 12; 22 |
Ratio of acetylation in both groups: control and treated with 2,3-butanedione.
| Protein I.D. | Gene I.D. | Peptide sequence | Acetylation ratio control group | Acetylation ratio treated group |
|---|---|---|---|---|
| AL1A1_RAT | ALDH1A1 | -.MSSPAQPAVPAPLANLKIQHTK.I | 1 | 3 |
| ANXA2_RAT | ANXA2 | K.ELPSAMKSALSGHLETVMLGLLK.T | 0.5 | 0.666666667 |
| ANXA2_RAT | ANXA2 | K.GVDEVTIVNILTNR.S | 0 | 1 |
| ANXA2_RAT | ANXA2 | K.SALSGHLETVMLGLLK.T | 0 | 1 |
| ANXA5_RAT | ANXA5 | K.YMTISGFQIEETIDRETSGNLENLLLAVVK.S | 0 | 1 |
| ASSY_RAT | ASS1 | R.GIYETPAGTILYHAHLDIEAFTMDR.E | 0 | 2 |
| BHMT1_RAT | BHMT | R.IASGRPYNPSMSKPDAWGVTK.G | 0 | 2 |
| CALR_RAT | CALR | K.HEQNIDCGGGYVK.L | 0 | 1 |
| CES1D_RAT | CES1D | K.GKVLGK.Y | 0 | 1 |
| CES1D_RAT | CES1D | R.SHRDAGAPTFMYEFEYRPSFVSAMRPK.T | 2 | 1.5 |
| DYH1_RAT | DNAH1 | R.SSLTRLASHMAEYECFQVELSK.N | 0 | 1 |
| EF2K_RAT | EEF2K | R.SGDLYTQAAEAAMEAMK.G | 0 | 1 |
| ENPL_RAT | HSP90B1 | R.MMKLIINSLYK.N | 0 | 2 |
| EPHA6_RAT | EPHA6 | R.EASIMGQFDHPNIIRLEGVVTK.R | 0 | 2 |
| FABPL_RAT | FABPL | K.SVTEFNGDTITNTMTLGDIVYK.R | 0 | 1 |
| FABPL_RAT | FABPL | K.YQVQSQENFEPFMK.A | 0 | 1 |
| G3P_RAT | GAPDH | K.RVIISAPSADAPMFVMGVNHEK.Y | 1 | 1.5 |
| OGA_RAT | MGEA5 | K.LDQVSQFGCRSFALLFDDIDHNMCAADK.E | 0 | 2 |
| PARK7_RAT | PARK7 | K.GAEEMETVIPVDIMR | 1 | 0.5 |
| PRC2A_RAT | PRRC2A | K.ALYPGALGRPPPMPPMNFDPRWMMIPPYVDPR.L | 1 | 0.5 |
| PRC2A_RAT | PRRC2A | K.AVGTPGGNSGGAGPGISTMSRGDLSQR.A | 0 | 2 |
| PRC2A_RAT | PRRC2A | R.ERSDSGGSSSEPFER.H | 0 | 1 |
| SI1L1_RAT | SIPA1L1 | K.EKSKPYPGAELSSMGAIVWAVR.A | 0 | 1 |
| SI1L1_RAT | SIPA1L1 | K.SLPLRRPSYTLGMK.S | 0 | 1 |
| STIP1_RAT | STIP1 | R.RAMADPEVQQIMSDPAMR.L | 0 | 1 |
| SYPM_RAT | PARS2 | K.GIEVGHTFYLGTKYSSIFNAHFTNAH GESLLAEMGCYGLGVTR.I | 1 | 2 |
| TBB4B_RAT | TUBB4B | R.INVYYNEATGGKYVPR.A | 0 | 2 |
| TPP1_RAT | TPP1 | R.EREPELAQLLVDQIYENAMIAAGLVDDPR.A | 0 | 1 |
| TPP1_RAT | TPP1 | R.INTLQAIWMMDPK.D | 0 | 1 |
| UBR4_RAT | UBR4 | K.ALGTLGMTTNEKGQVVTK.T | 0 | 1 |
| UBR4_RAT | UBR4 | K.EKAAPPPPPPPPPLESSPR.V | 0 | 2 |
| UBR4_RAT | UBR4 | K.EKEGESSGSQEDQLCTALVNQLNR.F | 1 | 1 |
| UBR4_RAT | UBR4 | K.FLSRPALPFILRLLR.G | 0 | 2 |
| UBR4_RAT | UBR4 | R.DNPEATQQMNDLIIGKVSTALK.G | 2 | 3 |
| UBR4_RAT | UBR4 | R.MAGVMAQCGGLQCMLNRLAGVK.D | 0 | 1 |
| UBR4_RAT | UBR4 | R.TGSTSSKEEDYESDAATIVQK.C | 0 | 2 |
| UD2B2_RAT | UGT2B | K.EWDTFYSEILGRPTTVDETMSKVEIWLIR.S | 0 | 2 |
Notes.
Mean ± Std. Error(N).
Figure 2Network of acetylated proteins in group treated with Diacetyl.
The green nodes are the proteins acetylated in group treated with Diacetyl but lack acetylation on treated groups. The red nodes are the proteins presents only in group treated with Diacetyl; the blue nodes are the proteins presents only in control group and the purple nodes are proteins present in both groups.
Figure 3Orthology analyses from more acetylated proteins in group treated with Diacetil than in control group.
(A) Molecular function; (B) biological process; (C) protein class; (D) cellular component.
Figure 4Motif analysis surrounding arginine, lysine and histidine acetylated peptides.
(A) Motif analysis of control group, surrounding acetylated arginine. (B) Motif analysis of control group, surrounding acetylated lysine. (C) Motif analysis of control group, surrounding acetylated histidine. (D) Motif analysis of group treated with diacetyl, surrounding arginine. (E) Motif analysis of group treated with diacetyl, surrounding lysine. (F) Motif analysis of group treated with diacetyl, surrounding histidine.
Figure 5Western blotting for acetylated proteins from lung samples.
(A) Western blotting 4 image: Lane 1: molecular weight; lanes 2–4: samples of the control group; lanes 5, 7, and 8: samples 5 of the diacetyl-treated group; and lanes 6, 9, and 10: sample buffer. (B) Western blotting quantification.